Every 10-Q that Staar Surgical Co (STAA) has filed with the SEC in the last 24 months is listed below, newest first, and each one links through to the document itself with the summary and the scores our analysis gives it.
A 10-Q covers the quarterly report filed between annual reports, so if you follow STAA and want that one kind of document rather than the whole filing history, this is the page to keep. The company's other filings, of every form, are on the full STAA filings page.
STAAR Surgical Company reported a strong turnaround for the quarter ended July 3, 2026. Net sales reached $93.5 million, up 111.0% from $44.3 million a year earlier, driven mainly by China, where two distributors generated $52.3 million of sales and 56% of quarterly revenue. Gross margin was 74.5%, slightly above 74.0% last year, reflecting cost reductions, partly offset by tariffs and higher unit costs during the ramp-up of the new Swiss facility.
Operating income was $10.1 million versus a loss of $(29.9) million, and net income was $8.1 million or $0.16 per diluted share compared with a loss of $(16.8) million or $(0.34) per share. For the first six months, net sales were $187.1 million and net income $13.3 million, versus a $(71.0) million loss in 2025, as prior-year restructuring and impairment charges of $27.9 million did not recur at the same scale.
Cash and investments available for sale totaled $181.5 million at July 3, 2026, up from $163.9 million at April 3, 2026, while operating cash outflow for the first half narrowed to $2.0 million from $33.0 million. The company notes ongoing ERP implementation challenges and continuing tariff pressure until it can supply 100% of EVO and EVO+ ICL lenses for China from Switzerland.
STAAR Surgical reported a strong turnaround for the quarter ended April 3, 2026. Net sales rose to $93.5 million, up 119.6% from a year earlier, driven mainly by China, where distributor sales reached $47.4 million and the EVO+ ICL launch was well received. Gross margin improved to 73.6% from 65.8% as prior cost-cutting and the Swiss manufacturing ramp began to benefit unit costs.
The company moved from a net loss of $54.2 million to net income of $5.2 million, or $0.10 per diluted share, even after $6.7 million of merger- and cooperation-related expenses and $2.7 million of restructuring charges. Operating cash flow was negative $21.7 million due to higher receivables and seasonal payments, but cash and investments remained solid at $163.9 million with working capital of $251.4 million.
Results highlight both rapid growth and concentration risk: China distributors represented 51% of net sales and 57% of trade receivables. Management expects to supply all EVO and EVO+ ICLs for China from Switzerland by the end of 2026, eliminating tariff exposure while continuing to focus on cost discipline and profitable growth.
STAAR Surgical Company (STAA) filed its Q3 report and detailed a pending merger with Alcon. Under the agreement, each share will be converted into $28.00 in cash at closing, subject to stockholder approval and other conditions. The HSR waiting period has expired, and the special meeting to vote on the merger is scheduled for December 3, 2025.
Q3 results: Net sales were $94.7 million versus $88.6 million a year ago, with gross margin at 82.2%. Net income was $8.9 million. Year‑to‑date net sales were $181.6 million versus $265.0 million, and the company reported a net loss of $62.1 million, reflecting $27.9 million in restructuring, impairment and related charges and $5.9 million in merger-related costs.
China dynamics remain central. Q3 China sales were $55.8 million, including $25.9 million recognized from a December 2024 shipment collected in Q3 at 100% gross margin. The company shifted to consignment arrangements in China and increased consigned inventory to manage tariff risk. Cash and equivalents were $176.2 million, with year‑to‑date operating cash flow of $(30.3) million. The board authorized a $30 million buyback; $23.5 million remained available as of quarter end.